Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine with or without Epoetin Beta in Low-risk MDS
NCT01015352Phase 2Completed
- Sponsor
- Groupe Français des Myélodysplasies
- Start
- Feb 2009
- Primary completion
- Mar 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of azacitidine in myelodysplastic syndrome (MDS), sponsored by Groupe Français des Myélodysplasies. Started Feb 2009; status: completed.
02
Drugs
azacitidine
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT01015352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01015352.